HJC0416 hydrochloride,HJC0416 hydrochloride

HJC0416 hydrochloride|T40056|TargetMol

價格	￥3810
包裝	10mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-09-29

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:HJC0416 hydrochloride	英文名稱:HJC0416 hydrochloride
CAS:2415263-08-8	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
產(chǎn)品類別: 抑制劑
貨號: T40056

Product Introduction

Bioactivity

名稱	HJC0416 hydrochloride
描述	HJC0416 hydrochloride, a potent, orally active inhibitor of STAT3, exhibits a superior anticancer profile compared to Stattic. It stands out as a promising agent for breast cancer research.
體外活性	HJC0416 hydrochloride inhibits the proliferation of both ER-positive, and ER-negative (triple negative) breast cancer cells with IC 50 values of 1.76 μM and 1.97 μM, respectively. However, it displays a marked antiproliferative effect against pancreatic cancer cell line AsPC1 and Panc-1 with IC 50 values of 40 nM and 1.88 μM, respectively[1].HJC0416 hydrochloride (1-10 μM; 48 hours) inhibits cell growth and induced apoptosis accompanying cellular morphological changes in MDA-MB-231 breast cancer cells[1].HJC0416 hydrochloride (5 μM; 24 hours) decreases the STAT3 promoter activity by approximately 51%, while stattic (HY-13818) only decreases the STAT3 promoter activity by 39% in MDA-MB-231 cells after transient transfecting with pSTAT3-Luc vector[1].HJC0416 hydrochloride (1-10 μM; 12 hours) has a comparable potency in downregulating STAT3 protein production and phosphorylation at Tyr-705 site when compares with Stattic (HY-13818). Additionally, it also induces cleaved caspase-3 and downregulated cyclin D1 levels in MDA-MB-231 cells[1]. Cell Cycle Analysis[1]Cell Line: MDA-MB-231 breast cancer cells Concentration: 1-10 μM Incubation Time: 48 hours Result: Induced cell apoptosis in cancer cells. Apoptosis Analysis[1]Cell Line: MDA-MB-231 breast cancer cells Concentration: 1 μM; 5 μM; 10 μM Incubation Time: 12 hours Result: Decreased p-STAT3 phosphorylation expression and cyclin D1 level.
體內(nèi)活性	HJC0416 hydrochloride (intraperitoneal?injection; 10 mg/kg; 7 days) shows a 67% decrease of tumor volume as compared to the control mice. Similarly, HJC0416 hydrochloride (oral administration; 100 mg/kg; 14 days) also significantly reduces tumor volume at a dose of 100 mg/kg by 46%. The i.p. route appeared to have a better reduction of tumor volume. It is also noteworthy that HJC0416 does not show significant signs of toxicity at a dose of 100 mg/kg[1]. Animal Model: Mice with MDA-MB-231 cells[1]Dosage: 10 mg/kg (i.p.); 100 mg/kg (oral) Administration: Intraperitoneal?injection, 7 days; oral administration, 14 days Result: Exhibited antitumor effects in the MDA-MB-231 triple-negative breast cancer murine xenograft model.
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
關(guān)鍵字	HJC-0416 Hydrochloride \| HJC 0416 Hydrochloride \| HJC-0416 hydrochloride \| HJC0416 hydrochloride \| HJC0416 Hydrochloride

關(guān)鍵字： HJC0416 hydrochloride|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計算機輔助藥物設(shè)計）研究中心、藥理實驗室、藥化合成平臺三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊資本	589.8595萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 1年

公司成立：12年
注冊資本：589.8595萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：抑制劑&激動劑，天然產(chǎn)物，重組蛋白，化合物庫，技術(shù)服務(wù)
公司地址：上海市靜安區(qū)江場三路238號8樓

進入店鋪

詢盤

店內(nèi)推薦

化合物 Glutathione maleimide|T70831|TargetMol

￥10600

化合物 Mcl1-IN-4|T11976|TargetMol

￥13800

化合物 Atorvastatin magnesium|T68467|TargetMol

￥13800